Zacks Research Has Negative Outlook of BIO Q1 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for Bio-Rad Laboratories in a research note issued to investors on Thursday, March 6th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $1.98 for the quarter, down from their previous forecast of $2.29. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $2.91 EPS, FY2025 earnings at $10.70 EPS, Q1 2026 earnings at $3.22 EPS, Q2 2026 earnings at $2.88 EPS and Q3 2026 earnings at $3.01 EPS.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%.

Several other analysts have also recently issued reports on the stock. Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $260.92 on Monday. The firm has a market capitalization of $7.31 billion, a price-to-earnings ratio of -4.01 and a beta of 0.98. The company has a 50 day moving average price of $319.72 and a 200 day moving average price of $330.35. Bio-Rad Laboratories has a one year low of $248.22 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Institutional Investors Weigh In On Bio-Rad Laboratories

Large investors have recently modified their holdings of the stock. Amalgamated Bank raised its stake in shares of Bio-Rad Laboratories by 119.7% during the third quarter. Amalgamated Bank now owns 9,033 shares of the medical research company’s stock valued at $3,022,000 after purchasing an additional 4,921 shares during the period. Principal Financial Group Inc. grew its holdings in Bio-Rad Laboratories by 95.6% during the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after purchasing an additional 21,669 shares in the last quarter. Assetmark Inc. increased its stake in Bio-Rad Laboratories by 84.8% during the 3rd quarter. Assetmark Inc. now owns 305 shares of the medical research company’s stock worth $102,000 after buying an additional 140 shares during the period. Atria Investments Inc lifted its holdings in Bio-Rad Laboratories by 9.2% in the 3rd quarter. Atria Investments Inc now owns 2,645 shares of the medical research company’s stock worth $885,000 after buying an additional 223 shares in the last quarter. Finally, Entropy Technologies LP purchased a new position in Bio-Rad Laboratories in the 3rd quarter valued at about $1,405,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.